Vaishali Pharma Ltd
NSE:VAISHALI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 5-Year Average (8.5), the stock would be worth ₹5.43 (29% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | ₹7.61 |
0%
|
| 5-Year Average | 8.5 | ₹5.43 |
-29%
|
| Industry Average | 47.3 | ₹30.37 |
+299%
|
| Country Average | 35.9 | ₹23.03 |
+203%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Vaishali Pharma Ltd
NSE:VAISHALI
|
815.7m INR | 11.9 | -159.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 39.7 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 19.6 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 45.4 | 12 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Vaishali Pharma Ltd
Glance View
Vaishali Pharma Ltd. is a healthcare company, which engages in the marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-08-22. The firm is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. In domestic markets, it is engaged in contract manufacturing and trading of active pharmaceuticals ingredient's (APIs) and supply of API's for export captive consumption. In export markets, it is engaged in manufacturing and export of pharmaceutical formulations; manufacturing and export of surgical products; manufacturing and export of veterinary products; and manufacturing and export of herbal and nutraceuticals products. Its product categories include API, formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. The firm markets approximately 400 products in domestic and APIs has a product portfolio of more than 1,000 products for the overseas market.
